|Articles|October 1, 2001
Study finds risk of BCC/SCC high in melanoma patients
UV exposure, in chronic and intermittent intense exposures, may becommon link for association
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.